Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provided earnings guidance for the period from January 1, 2022 to June 30, 2022. For the period, the company expected Net profit attributable to shareholders of the listed company to be in range of RMB 473.500 million to RMB 542.000 million Increase as compared with the corresponding period: 40.02% to 60.28%. and Basic earnings per share RMB 0.3227 per share to RMB0.3694 per share.

Reasons for changes in the results: (1) During the reporting period, the Company's operating income achieved rapid growth. Benefiting from the continuous development of the Company's enoxaparin sodium finished dose in various regions around the world and the stable growth of API business orders, the Company's heparin industry chain business income achieved rapid growth; meanwhile, based on the further growth of orders in hand and the continuous improvement of on-time and successful delivery rate, the Company's CDMO business income maintained a steady and promising growth trend. (2) During the reporting period, the profitability of the Company continued to improve.

On the one hand, the Company actively promoted the strategy of improving the management and operation efficiency of the global supply chain, and its effective implementation and execution have achieved periodical results; on the other hand, benefiting from the continuous decrease in the price of raw materials in the second half of 2021, taking into account the factors of production and sales cycle, the decrease in purchase price of raw materials resulted in the gradual decrease in sales cost during the reporting period, and the gross profit margin showed rebound, resulting in an improvement in the Company's overall profitability.